Phase I drug. Already has API HPLC stability-indicating method. Forced degradation was performed on API (acid/base, oxidation, light, thermal/humidity). Excipient compatibility was performed too (thermal/humidity).
Now drug product stability-indicating method is under development based on API method.
In this case above, is the forced degradation mandatory for drug product? can we skip it since we've already performed API forced deg study and 6 month excipient compatibility study?
Thanks!
Apple
Hi,
It is better to do the
forced degradation of the
drug product along with the API as it gives better insight into the molecule. It also helps to build confidence in the analytical method used for the same. The regulatory agency will also ask for the data if not submited during the IND filing and this comes out as a deficeincy letter . So why to delay things , just do it and be on safer side.... isn't it??
Regards,
Yogesh